The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer.
 
Emma Hall
Research Funding - Accuray (Inst); AstraZeneca (Inst); Aventis Pharma (Inst); Bayer (Inst)
 
Syed A. Hussain
Consulting or Advisory Role - Astellas Pharma; Bayer; Pierre Fabre
Research Funding - Boehringer Ingelheim; Janssen-Cilag; Pierre Fabre
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Boehringer Ingelheim; Janssen-Cilag; MSD Oncology; Pfizer; Pierre Fabre; Roche
 
Nuria Porta
No Relationships to Disclose
 
Malcolm Crundwell
No Relationships to Disclose
 
Peter Jenkins
No Relationships to Disclose
 
Christine Lisa Rawlings
No Relationships to Disclose
 
Jean Tremlett
No Relationships to Disclose
 
Charlotte Friend
No Relationships to Disclose
 
Clive Stubbs
No Relationships to Disclose
 
Rebecca Lewis
No Relationships to Disclose
 
Nicholas D. James
Honoraria - Astellas Pharma; Bayer; Janssen; Oncogenex; Pierre Fabre; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Merck; Sanofi
Speakers' Bureau - Astellas Pharma; Ferring; Pierre Fabre; Sanofi
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Robert Anthony Huddart
Leadership - Cancer Clinic London Limited Liability Partnership
Consulting or Advisory Role - Astellas Pharma; Merck Sharp & Dohme
Research Funding - Janssen; Lilly; Roche